May be considered after confirming persistent low desire with distress and reviewing relationship, medication, hormonal, pain, mood and medical contributors.
SEXUAL WELLNESS / PRACTITIONER-GUIDED
Female sexual-desire medications
Flibanserin and bremelanotide are distinct FDA-approved options for narrow acquired, generalized HSDD populations—not universal libido enhancers.Create account & prepare for review →Practitioner review required · A prescription is never guaranteed.
Randomized human evidence supports modest average benefit for labeled populations; product selection and safety requirements differ.
Prescription required; narrow product-specific FDA indications
WHO MAY BE CONSIDERED
Eligibility starts with your complete health context.
- ✓Low desire is persistent, generalized and personally distressing
- ✓Medication, relationship, pain, mood and medical contributors are assessed
- ✓The patient matches the chosen product’s labeled population and safety requirements
WHAT A PRACTITIONER REVIEWS
The information that shapes the decision.
- →Menopause status and symptom pattern
- →Alcohol, blood pressure, liver function and interacting medicines
- →Pregnancy plans, sexual pain and relationship or mental-health context
IMPORTANT SAFETY INFORMATION
Reasons treatment may not be appropriate.
- !These medications do not treat sexual pain, relationship distress or low desire caused by another untreated condition.
- !Flibanserin has important hypotension, syncope, alcohol and drug-interaction precautions.
- !Bremelanotide can raise blood pressure and commonly causes nausea; cardiovascular risk must be reviewed.
ORIGINAL SOURCES